Risk for Colorectal Neoplasia in Patients With Colonic Crohns Disease and Concomitant Primary Sclerosing Cholangitis
Clinical Gastroenterology and Hepatology , Braden B et al.
Primary sclerosing cholangitis (PSC) does not seem to increase the risk for dysplasia of the colon in patients with colonic Crohn's disease.
The authors performed a retrospective review of data from a tertiary care hospital on 166 patients with PSC and inflammatory bowel disease; 120 had concomitant ulcerative colitis, 35 had Crohn's disease, and 11 had indeterminate colitis.
The controls comprised 114 patients with colonic involvement of Crohn's disease and 102 patients with ulcerative colitis.
The main outcome parameter was the development of colorectal cancer or intraepithelial neoplasia.
Only 1 patient with colonic Crohn's disease and concomitant PSC developed dysplasia in an adenomatous polyp during a median follow-up of 10 years (range, 7–16 years).
In contrast, 2 cancers and 8 cases of colorectal dysplasia were diagnosed in patients with ulcerative colitis and PSC during a median follow up of 11 years (range, 8–16 years); the crude annual incidence of dysplasia or colorectal cancer was 1 in 150 patients with ulcerative colitis.
Among patients with colonic Crohn's disease without PSC, 2 developed colorectal cancer during follow-up.
The presence of PSC did not increase the risk of developing colorectal dysplasia in patients with Crohn's disease (P = 1.00).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.